Nicholas Saraceno, Editor

In an interview with Pharma Commerce Editor Nicholas Saraceno, Matt Hawkins, CaryHealth’s Chief Technology Officer, describes how artificial intelligence can not only diagnose patients, but also deliver accurate medical advice.

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, predicts the likelihood of stabilization period postponement.

The facility will focus on furthering RNA and DNA-based therapies.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

The partnership creates an integrated solution that also tackles compliance challenges within the sector.

In the final part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, defines the qualifying characteristics of a specialty lite product, and summarizes the main points of his Asembia panel.

Ongoing education on the people and topics we cover is critical—with one recent webinar I attended a fitting example.

A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.

The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.

In this part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, discusses the impact technology has in relation to patients sticking to their medication plan.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence.

The Silverpod MAX RE offers real-time shipment visibility, while also helping companies accomplish their sustainability goals.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

The CDMO will also be adding new equipment for the manufacture of oligonucleotides and peptides.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In the final portion of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the value in needle-to-needle and precision logistics, including its impact over the course of the next five years.

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the development of frozen/cold biologics when it comes to the logistics space, along with how the companies themselves have changed over the years.

The climb is headlined by a 14.1% increase in total demand, according to the IATA.

Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The agreement focuses on augmenting the patient support experience, including from an adherence perspective.

The partnership—which features a $150 million investment—is also centered around vaccine development in the respiratory and immunology space.